Effect of Glucose Degradation Products (GDP) on Endothelial Dysfunction

• Status: Completed
• Trial end date: 2008-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the effects of neutral pH and low glucose degradation product (GDP)-containing peritoneal dialysis fluid (PDF) on systemic inflammation and endothelial dysfunction markers in incident PD patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kyungpook National University; Kyungpook National University Hospital
• Collaborators: Fresenius Medical Care Korea; Ministry of Health & Welfare, Korea

Criteria

Inclusion Criteria:

• Male and female patients aged over 18 years and less than 75 years

• Within 90 days of initiation of first renal replacement treatment for ESRD

• Selected for maintenance management by CAPD

• Having provided informed consent

• Physically and mentally capable of performing the therapy

Exclusion Criteria:

• Patients were excluded if deemed to have less than 80% likelihood of survival for at least 1 year

• episodes of peritonitis within prior 30 days

• any malignancy other than treated skin carcinoma

• uncontrolled congestive heart failure

• recent (within 60 days) myocardial infarction or cerebrovascular accident

• active systemic vasculitic disease including systemic lupus erythematosus, polyarteritis nodosa, ANCA-nephritis, active rheumatoid disease, or active venous thrombotic-embolic disease

• any acute infection at the time of enrollment

• active or actively treated tuberculosis

• recent (within 30 days) systemic bacterial infection.